Pralatrexate for Relapsed or Refractory Peripheral T-cell Lymphoma

Overview

A non-interventional, multicenter, multinational retrospective analysis using electronic case report forms completed by the investigators based on information from patient medical records

Full Title of Study: “Pralatrexate for Relapsed or Refractory Peripheral T-cell Lymphoma: a Multicenter, Multinational Retrospective Analysis”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Retrospective
  • Study Primary Completion Date: June 30, 2017

Detailed Description

All patients who satisfy the inclusion criteria for this study in each participating institution will be included. Considering the number of participating centers in Korea, Latin America (Mexico, Colombia), and Europe (Switzerland, Israel), the expected number of patients is 50. This research involves only the collection and analysis of existing data, documents, and records. The information will be recorded by the investigators on a CRF in a way that the subjects cannot be identified directly or through identifiers linked to the subjects. Thus, this study should be reviewed and approved by the Institutional Review Board of each participating institute, and exemption from additional written informed consent should be applied. 1. Age, sex, nationality, ethnicity 2. Ann Arbor stage, disease involved sites, number of extranodal involvement, serum LDH concentration, ECOG performance status, presence of B symptoms, regional lymph node involvement, International Prognostic Index, bone marrow invasion at the time of pralatrexate treatment 3. Dose and schedule of pralatrexate, start date, last treatment date, other treatment modalities

Interventions

  • Drug: Pralatrexate
    • Patients treated with pralatrexate due to relapse or refractory disease after primary and/or salvage treatment. Relapse following an autologous stem cell transplant allowed. Patients treated with pralatrexate 30mg/m2 once a week for 6 weeks as part of a 7-week cycle. However, modified dose and/or schedule allowed.

Clinical Trial Outcome Measures

Primary Measures

  • Overall response rate (ORR) including complete remission (CR) and partial remission (PR)
    • Time Frame: This is a restrospective study. Data collection and analysis will be done for 6 months.
    • retrospective analysis using electronic case report forms completed by the investigators based on information from patient medical records

Secondary Measures

  • Progression-free survival (PFS)
    • Time Frame: This is a restrospective study. Data collection and analysis will be done for 6 months.
    • retrospective analysis using electronic case report forms completed by the investigators based on information from patient medical records
  • Overall survival (OS)
    • Time Frame: This is a restrospective study. Data collection and analysis will be done for 6 months.
    • retrospective analysis using electronic case report forms completed by the investigators based on information from patient medical records
  • Duration of response (DoR)
    • Time Frame: This is a restrospective study. Data collection and analysis will be done for 6 months.
    • retrospective analysis using electronic case report forms completed by the investigators based on information from patient medical records
  • Toxicity
    • Time Frame: This is a restrospective study. Data collection and analysis will be done for 6 months.
    • This study will investigate the number of participants with grade 3-4 neutropenia, grade 3-4 thrombocytopenia, grade 3-4 anemia and grade 4 febrile neutropenia according to CTCAE v4.0. This study will also investigate the number of participants with nausea, anorexia, constipation, diarrhea, peirpheral neuropathy, and skin rash that are related pralatrexate treatment according to CTCAE v4.0.
  • Tolerability
    • Time Frame: This is a restrospective study. Data collection and analysis will be done for 6 months.
    • This study will investigate the dose intensity of pralatrexate based in information from patient medical records.

Participating in This Clinical Trial

Inclusion Criteria

  • 1. Histologically confirmed peripheral T-cell lymphoma according to following inclusion criteria of subtypes according to the 2016 revision of the World Health Organization classification of lymphoid neoplasm 1. Adult T-cell leukemia/lymphoma 2. Angioimmunoblastic T-cell lymphoma 3. Anaplastic large cell lymphoma, ALK positive 4. Anaplastic large cell lymphoma, ALK negative 5. Peripheral T-cell lymphoma, NOS 6. Enteropathy-type intestinal lymphoma 7. Hepatosplenic T-cell lymphoma 8. Extranodal NK/T-cell lymphoma, nasal type 9. Subcutaneous panniculitis-like T-cell lymphoma 10. Transformed mycosis fungoides 11. Mycosis fungoides 12. Sézary syndrome 13. Primary cutaneous CD30+T-cell lymphoproliferative disorder (primary cutaneous anaplastic large cell lymphoma) 14. Primary cutaneous gamma-delta T-cell lymphoma 2. Age ≥ 18 years old 3. Patients treated with pralatrexate due to relapse or refractory disease after primary and/or salvage treatment. Relapse following an autologous stem cell transplant allowed. 4. Patients treated with pralatrexate 30mg/m2 once a week for 6 weeks as part of a 7-week cycle. However, modified dose and/or schedule allowed. Exclusion Criteria:

  • 1. Histologically confirmed peripheral T-cell lymphoma with following exclusion criteria of subtypes 1. Aggressive NK-cell leukemia 2. T-cell prolymphocytic leukemia 3. T-cell large granular lymphocytic leukemia 4. Primary cutaneous CD30+ T-cell lymphoproliferative disorders (lymphomatoid papulosis) 2. Patients with active/symptomatic central nervous system (CNS) involvement. 3. HIV-related lymphoma 4. Prior allogeneic stem cell transplant within 6 months. 5. Concurrent active or history of other malignancies. 6. Concurrent uncontrolled serious medical or psychiatric conditions

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Samsung Medical Center
  • Provider of Information About this Clinical Study
    • Principal Investigator: Won Seog Kim, MD – Samsung Medical Center

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.